T1	Participants 61 99	acute myelogenous leukemia in relapse:
T2	Participants 130 235	Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy
T3	Participants 514 525	25 patients
T4	Participants 566 568	23